search
Back to results

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

Primary Purpose

Acute Pain

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
ADL5859 30 mg
ADL5859 100 mg
ADL5859 200 mg
ibuprofen 400 mg
Sponsored by
Cubist Pharmaceuticals LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Pain focused on measuring delta opioid agonist, dental pain

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • have 2 or more 3rd molars requiring extraction, including at least 1 partially or completely bone-impacted mandibular molar
  • experience moderate to severe pain intensity as measured by the Numeric Pain Rating Scale (NPRS) (score ≥ 5) within 6 hours after surgery
  • for male subjects, be surgically sterile or agree to use an appropriate method of contraception or have a sexual partner who is surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive
  • for female subjects, be using contraceptives, be postmenopausal, or have undergone hysterectomy or tubal ligation
  • be able to take oral study medications

Key Exclusion Criteria:

  • have positive results either on the urine screening tests for opiates, tetrahydrocannabinol,cocaine, amphetamines, barbiturates, benzodiazepines, phencyclidine, or propoxyphene or on the alcohol breathalyzer test
  • have a history of alcoholism or drug addiction or abuse within 5 years before dosing with study medication
  • have a history of chronic use (defined as daily use for > 2 weeks) of glucocorticoids,nonsteroidal anti-inflammatory drugs, or opiates for any condition within 6 months of study medication administration
  • have a known allergy or history of significant reaction to any of the known treatment medications (ADL5859-like compounds or ibuprofen) or rescue pain medication (acetaminophen)
  • have significant renal or hepatic disease, as indicated by clinical laboratory assessment
  • have a known history of epilepsy or seizure disorder, including history of febrile seizure, or any other medical or psychiatric condition that, in the judgment of the investigator, would put the subject at risk while in the study, could influence the results of the study, or could negatively affect the subject's ability to participate in the study
  • have a history or evidence of orthostatic hypotension at screening have a history of significant head trauma (head injury with loss of consciousness)

Sites / Locations

  • SCIREX Research Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Placebo

ADL5859 30 mg

ADL5859 100 mg

ADL5859 200 mg

ibuprofen 400 mg

Arm Description

Outcomes

Primary Outcome Measures

Total pain relief 0-4 hours after study medication

Secondary Outcome Measures

Full Information

First Posted
October 9, 2009
Last Updated
July 16, 2015
Sponsor
Cubist Pharmaceuticals LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00993863
Brief Title
Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction
Official Title
A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled Study of ADL5859 for the Treatment of Pain After Surgical Removal of Impacted Third Molars
Study Type
Interventional

2. Study Status

Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
September 2007 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Cubist Pharmaceuticals LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pain
Keywords
delta opioid agonist, dental pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
201 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
ADL5859 30 mg
Arm Type
Experimental
Arm Title
ADL5859 100 mg
Arm Type
Experimental
Arm Title
ADL5859 200 mg
Arm Type
Experimental
Arm Title
ibuprofen 400 mg
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
single dose
Intervention Type
Drug
Intervention Name(s)
ADL5859 30 mg
Intervention Description
single dose
Intervention Type
Drug
Intervention Name(s)
ADL5859 100 mg
Intervention Description
single dose
Intervention Type
Drug
Intervention Name(s)
ADL5859 200 mg
Intervention Description
single dose
Intervention Type
Drug
Intervention Name(s)
ibuprofen 400 mg
Other Intervention Name(s)
Advil
Intervention Description
single dose
Primary Outcome Measure Information:
Title
Total pain relief 0-4 hours after study medication
Time Frame
4 hours after study medication

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: have 2 or more 3rd molars requiring extraction, including at least 1 partially or completely bone-impacted mandibular molar experience moderate to severe pain intensity as measured by the Numeric Pain Rating Scale (NPRS) (score ≥ 5) within 6 hours after surgery for male subjects, be surgically sterile or agree to use an appropriate method of contraception or have a sexual partner who is surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive for female subjects, be using contraceptives, be postmenopausal, or have undergone hysterectomy or tubal ligation be able to take oral study medications Key Exclusion Criteria: have positive results either on the urine screening tests for opiates, tetrahydrocannabinol,cocaine, amphetamines, barbiturates, benzodiazepines, phencyclidine, or propoxyphene or on the alcohol breathalyzer test have a history of alcoholism or drug addiction or abuse within 5 years before dosing with study medication have a history of chronic use (defined as daily use for > 2 weeks) of glucocorticoids,nonsteroidal anti-inflammatory drugs, or opiates for any condition within 6 months of study medication administration have a known allergy or history of significant reaction to any of the known treatment medications (ADL5859-like compounds or ibuprofen) or rescue pain medication (acetaminophen) have significant renal or hepatic disease, as indicated by clinical laboratory assessment have a known history of epilepsy or seizure disorder, including history of febrile seizure, or any other medical or psychiatric condition that, in the judgment of the investigator, would put the subject at risk while in the study, could influence the results of the study, or could negatively affect the subject's ability to participate in the study have a history or evidence of orthostatic hypotension at screening have a history of significant head trauma (head injury with loss of consciousness)
Facility Information:
Facility Name
SCIREX Research Center
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

We'll reach out to this number within 24 hrs